Dr. David Mazzo: And if I may, I’ll just add one additional commentary. And once again, I’ll bounce it back to Kristen. When you talked about, Steve, how the medical communities reacting and what the level of enthusiasm is, I think Kristen can provide some real insight to that based on her recent visits at the ASCO conference in June.
Dr. Kristen Buck: Sure, Dave. We — the team visited the ASCO conference in June to socialize the BOLSTER trial, which is the solid tumor trial in cholangiocarcinoma, head and neck and esophageal carcinoma. We had tremendous interest from KOLs across the United States and around the world, including China, wanting to evaluate our product not only in the BOLSTER trial but in other trials where they felt this asset would be most effective. So it was very heartening to see that the news is getting out that this drug has the ability to be a platform play and that we have really interesting PIs who are eager to be part of our study.
Operator: Our next question comes from Pete Enderlin with MAZ Partners.
Pete Enderlin: Congratulations on the multiplicity of programs that you’re standing up at this point. First question is, does the cash runway that you’ve projected of close to 11 quarters include some assumption about milestone payments?
Dr. David Mazzo: Pete, thanks very much for your kind words. At this point, our cash projections do not include any projections of incoming capital except perhaps for the remaining available capital for which we are eligible from the New Jersey NOL program. But we are not looking at milestone pay, or we have not considered milestone payments, capital raises or any other BD or M&A deals in that projection. So it’s a very conservative projection.
Pete Enderlin: Okay. And over that close to three-year period, is it possible that there will be some milestone payments or you’re just sort of not — I mean, you’re not counting on them, but are there ones that could happen in that timeframe?
Dr. David Mazzo: Yes, there are. We have a publicly announced license deal with Qilu Pharmaceuticals in China which has developments and regulatory milestones built into it. And there is — I’d say a reasonable possibility that some of those milestones could be achieved over the course of the next several years.
Pete Enderlin: Okay. And then on the transfer of the TPN technology, are there any potential royalties included in that if such should be possible? I mean sales eventuate?
Dr. David Mazzo: Yes, so that the TPN deal is a typical deal, in that we have transferred the asset to another party, which will finance its development and we’ve retained a proportion of ownership in that, and we expect that we’ll also have the ability to achieve future benefit from sales and other deals should they occur.
Pete Enderlin: Other than the ownership portion, would you actually have and is it written into the agreement that there would be royalties?
Dr. David Mazzo: Off the top of my head, I don’t recall that at this point, Steve. But John can get back to you post meeting after we go back to the contract. It was just recently signed. And I don’t recall if it has any specific royalties in the offer, it just starts with the substantial equity ownership in Impilo.
Pete Enderlin: Okay. And can I ask one more? Do you want me to jump back in the queue.
Dr. David Mazzo: Go ahead and finish up, Pete.
Pete Enderlin: Okay. The press release mentioned possible conditional approvals for the ASCEND trial. And the question first is are protocols for conditional approval in various regulatory agencies around the world pretty similar? Or would it vary a lot by which country you’re talking about?
